Deutsche Märkte geschlossen

Adverum Biotechnologies, Inc. (ADVM)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
14,09-0,57 (-3,89%)
Ab 03:05PM EDT. Markt geöffnet.

Adverum Biotechnologies, Inc.

100 Cardinal Way
Redwood City, CA 94063
United States
650 656 9323
https://adverum.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter121

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Laurent FischerPresident, CEO & Director1,02MN/A1964
Ms. Linda M. Rubinstein M.A.CFO, Principal Financial Officer & Principal Accounting Officer940,99kN/A1967
Mr. Kishor Peter Soparkar J.D.Chief Operating Officer674,98kN/A1972
Dr. Setareh Seyedkazemi Pharm.D.Chief Development Officer656,84kN/A1975
Dr. R. Andrew Ramelmeier Ph.D.Chief Technology OfficerN/AN/A1962
Dr. Romuald Corbau Ph.D.Chief Scientific OfficerN/AN/A1969
Mr. John W. Rakow J.D.Senior VP & General Counsel954,24kN/A1957
Ms. Dena HouseChief People OfficerN/AN/AN/A
Ms. Carla FiankanSenior Vice President of Regulatory AffairsN/AN/AN/A
Mr. Michael SteelSenior Vice President of QualityN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Corporate Governance

Adverum Biotechnologies, Inc.s ISS Governance QualityScore, Stand 1. März 2024, lautet 7. Die grundlegenden Scores sind Audit: 6, Vorstand: 5, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.